CHECKPOINT THER. DL-0001
Checkpoint Therapeutics, Inc., a commercial -stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is UNLOXCYT, which is in Phase 1 clinical trial to treat patients with selected recurrent or m… Read more
CHECKPOINT THER. DL-0001 (CZTA) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, CHECKPOINT THER. DL-0001 (CZTA) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
CHECKPOINT THER. DL-0001 - Net Assets Trend (None–None)
This chart illustrates how CHECKPOINT THER. DL-0001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CHECKPOINT THER. DL-0001 (None–None)
The table below shows the annual net assets of CHECKPOINT THER. DL-0001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to CHECKPOINT THER. DL-0001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
CHECKPOINT THER. DL-0001 Competitors by Market Cap
The table below lists competitors of CHECKPOINT THER. DL-0001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MBIA Inc
NYSE:MBI
|
$266.23 Million |
|
TATTON ASSET MANAG.LS-20
F:2T7
|
$266.24 Million |
|
HaiXin Foods Co Ltd
SHE:002702
|
$266.25 Million |
|
Multiconsult AS
OL:MULTI
|
$266.28 Million |
|
Zhengzhou Qianweiyangchu Food Co Ltd
SHE:001215
|
$266.09 Million |
|
NATL RESH CORP. DL-001
F:NR1A
|
$265.98 Million |
|
Skellerup Holdings Limited
PINK:SKLUY
|
$265.97 Million |
|
Zhejiang Jiaxin Silk Corp Ltd
SHE:002404
|
$265.95 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CHECKPOINT THER. DL-0001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares CHECKPOINT THER. DL-0001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently CHECKPOINT THER. DL-0001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares CHECKPOINT THER. DL-0001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CHECKPOINT THER. DL-0001 (CZTA) | €- | N/A | N/A | $266.10 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |